RT Journal Article
T1 Absence of relevant QT interval prolongation in not critically ill COVID-19 patients
A1 Jiménez-Jáimez, Juan
A1 Macías-Ruiz, Rosa
A1 Bermúdez-Jiménez, Francisco
A1 Rubini-Costa, Ricardo
A1 Ramírez-Taboada, Jessica
A1 García Flores, Paula Isabel
A1 Gallo-Padilla, Laura
A1 Mediavilla García, Juan Diego
A1 Morales García, Concepción
A1 Moreno Suárez, Sara
A1 Fignani Molina, Celia
A1 Álvarez López, Miguel
A1 Tercedor, Luis
K1 COVID-19
K1 Anti-bacterial agents
K1 Antimalarials
K1 Azithromycin
K1 Drug therapy, combination
K1 Antiviral agents
K1 Farmacorresistencia bacteriana
K1 Antimaláricos
K1 Azitromicina
K1 Quimioterapia combinada
K1 Antivirales
K1 Factores de riesgo
AB SARS-CoV-2 is a rapidly evolving pandemic causing great morbimortality. Medical therapy with hydroxicloroquine, azitromycin and protease inhibitors is being empirically used, with reported data of QTc interval prolongation. Our aim is to assess QT interval behaviour in a not critically ill and not monitored cohort of patients. We evaluated admitted and ambulatory patients with COVID-19 patients with 12 lead electrocardiogram at 48 h after treatment initiation. Other clinical and analytical variables were collected. Statistical analysis was performed to assess the magnitude of the QT interval prolongation under treatment and to identify clinical, analytical and electrocardiographic risk markers of QT prolongation independent predictors. We included 219 patients (mean age of 63.6 ± 17.4 years, 48.9% were women and 16.4% were outpatients. The median baseline QTc was 416 ms (IQR 404-433), and after treatment QTc was prolonged to 423 ms (405-438) (P < 0.001), with an average increase of 1.8%. Most of the patients presented a normal QTc under treatment, with only 31 cases (14.1%) showing a QTc interval > 460 ms, and just one case with QTc > 500 ms. Advanced age, longer QTc basal at the basal ECG and lower potassium levels were independent predictors of QTc interval prolongation. Ambulatory and not critically ill patients with COVID-19 treated with hydroxychloroquine, azithromycin and/or antiretrovirals develop a significant, but not relevant, QT interval prolongation.
PB Springer Nature
YR 2020
FD 2020-12-08
LK http://hdl.handle.net/10668/3445
UL http://hdl.handle.net/10668/3445
LA en
NO Jiménez-Jáimez J, Macías-Ruiz R, Bermúdez-Jiménez F, Rubini-Costa R, Ramírez-Taboada J, García Flores PI, et al. Absence of relevant QT interval prolongation in not critically ill COVID-19 patients. Sci Rep 10, 21417 (2020).
DS RISalud
RD Apr 6, 2025